Hyperthermia Blog

News and Opinions About Our Industry

In the last few weeks, Pyrexar products were being presented at conferences in Warsaw, Poland; Miami, Florida; Barcelona, Spain; and Münster, Germany.  So thankful for our great partners educating oncologists and physicists, all over the world, to the benefits of hyperthermia in the treatment of cancer. We wanted to share a few images of these events with you.

ESHO - Warsaw, Poland

Pyrexar ESHO Award

2019 Pyrexar ESHO Award

The ESHO-Pyrexar Award, presented by Dr. Sennewald Medizintechnik Gmbh, is awarded annually for outstanding contributions to hyperthermic oncology, education, and scientific achievement. This year's recipient is Prof. Dr. med. Lars Lindner.  Dr. Lindner is a respected thermal oncologist and researcher, well known for the landmark study "Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma" published in Jama earlier this year.  We congratulate him and his team for their contributions to thermal medicine. More information about ESHO (European Society for Hyperthermic Oncology) can be found here.


SEOR - Barcelona, Spain

Pyrexar at SEOR 2019

This was our first time at the SEOR (Spanish Society of Radiation Oncology) in Spain, represented by our distributor Magna Medic Systems based in Málaga, Spain.  The organization has been making tremendous strides in the introduction of hyperthermia to oncologists in the region.


DEGRO - Münster, Germany

Pyrexar represented at the DEGRO 2019

Our distribution partner, Dr. Sennewald Medizintechnik Gmb, was a silver sponsor at DEGRO (German Society of Radiation Oncology) and held a lunch symposium focused on reimbursement issues in Germany.


ABS - Miami Florida

Pyrexar Medical exhibiting at the ABS 2019

This was Pyrexar's first engagement at the ABS (American Brachytherapy Society).  Our goal was to demonstrate that adding hyperthermia as an adjunct to brachytherapy boosted the effectiveness of this radiotherapy treatment without interrupting workflow. It was an excellent show and we will be back next year.

Pyrexar will be exhibiting at this year's ABS (American Brachytherapy Society) annual meeting in Miami, Florida. The conference will be held at the Intercontinental Miami hotel, June 13th through the 15th.

Pyrexar exhibits at the American Brachytherapy Society annual meeting miami florida

This is our first time exhibiting at the conference and we believe we have a compelling solution to offer. HDR (high dose rate) brachytherapy and hyperthermia share some of the same market challenges. The bottom line is that brachytherapy plus hyperthermia improve cancer patient outcomes.

Like hyperthermia, brachytherapy is a sub-specialty that requires a specific skill set to treat patients. And like hyperthermia, brachytherapy is known to produce increased tumor control without an increase in toxicity. Product planning for hyperthermia is very similar and the system utilizes the existing brachy catheters placed during HDR.

This month the 33rd Annual Meeting of the European Society for Hyperthermic Oncology (ESHO 2019), will be held in Warsaw, Poland, at the Warsaw Plaza Hotel, on May 22 - 24, 2019. The conference invites thermal oncology professionals with the extensive clinical and scientific experience to share their experience in the field.

ESHO 2019 Warsaw, PolandPyrexar Medical will be represented by our European distribution partner Dr. Sennewald Medizintechnik and Poland distributor HT Systems.

Pyrexar Represented by:

Dr. Sennewald Medizintechnik Hyperthermia medical device company HT systems Hyperthermia medical device company

 The conference includes over 58 presentations by leading hyperthermia experts. Highlights below:

MR thermometry validation and modeling of a 915 MHz annular phased-array in brain phantoms Paul Turner
A meta-analysis of clinical trials with hyperthermia Niloy Datta
Protons and hyperthermia: early clinical results Zeljko Vujaskovic
Building an international forum to boost hyperthermic research Stephan Bodis
Quality assurance guidelines for hyperthermia H. Dobsicek Trefna
Quality assurance assessment: are commercial MR-guided deep-pelvic hyperthermia devices ready for a large clinical trial? Sergio Curto
QA techniques for radiative deep hyperthermia systems: benefits and limitations of 1D, 2D, and 3D techniques Gerard van Rhoon
Combined interstitial radiotherapy with interstitial hyperthermia Andrzej Kukielka
Thermochemoradiotherapy for locally advanced pancreatic cancers: A pilot study Niloy Datta
Radiotherapy in combination with regional Hyperthermia for Salvage Treatment in refractory Childhood Cancer Rudiger Wessalowski
Full program available here.

A special thanks to the 2019 ESHO committee for organizing this year's event and to the Maria Sklodowska-Curie Institute — Oncology Center for hosting the hyperthermia workshops.

estro38 Dr. Sennewald Medizintechnik, Pyrexar's European distribution partner,  has brought together an impressive program of clinicians to talk about hyperthermia's role in the treatment of cancer, at this years ESTRO 38 (European Society for Radiotherapy & Oncology).  The luncheon symposium titled "Hyperthermia in the age of personalized oncology" will be held Saturday, April 27th and is open to all ESTRO attendees (space is limited).

Program outline below:

Introduction Daniel Zips, UMC Tübingen, Germany
Hyperthermia as immune modulator in multimodal tumor therapies - immune biological rationale Michael Hader, PhD, UMC Erlangen, Germany
Integration of Pencil Beam Scanning Proton Therapy and Hyperthermia: The University of Maryland Clinical Experience Zeljko Vujaskovic MD, University of Maryland, USA
Management of locally recurrent Breast Cancers with local hyperthermia and radiotherapy: A systematic review and meta-analysis Niloy Datta MD, Canton Hospital Aarau, Switzerland
Neoadjuvant chemotherapy combined with regional deep hyperthermia as the new standard for the treatment of patients with high-risk soft tissue sarcomas Lars Lindner MD,  UMC Munich Grosshadern, Germany
Hyperthermia and preoperative chemoradiation for organ-preservation in rectal cancer patients Cihan Gani MD, UMC Tübingen, Germany
Discussion and Summary Stephan Bodis MD, Canton Hospital Aarau, Switzerland

ABOUT ESTRO

Founded in 1980, ESTRO, the European SocieTy for Radiotherapy & Oncology, is a non-profit and scientific organization that fosters the role of Radiation Oncology in order to improve patients’ care in the multimodality treatment of cancer. ESTRO 38 is being held in Milan, Italy, April 26th - 30th, 2019 at the Milan Convention Center.

Hands-On CME Training Class from the World's Leading Experts

Countdown to the University of Maryland CME-Credited Thermal Oncology Educational Program, Oct 18-19. See Program Details